Scribe Therapeutics market cap: $502.257 M

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

#63AgomAb TherapeuticsAGMB$530.2M
#64Autolus TherapeuticsAUTL$519.0M
#65Scribe TherapeuticsSCTX$502.3M
#66ProkidneyPROK$498.8M
#67RegenxbioRGNX$495.1M

Insiders buying

6 open-market purchases by officers and directors of Scribe Therapeutics, worth $71.3M. Grants and option exercises are excluded.

ORBIMED ADVISORS LLC, OrbiMed Capital GP VIII LLC$15.0M
1,000,000 shares at $15.00 on 27 Jul 2026 · filed 29 Jul 2026
Carl L. Gordon$15.0M
1,000,000 shares at $15.00 on 27 Jul 2026 · filed 29 Jul 2026
AH Bio Fund II, L.P., AH Bio Fund III, L.P., AH Equity Partners Bio II, L.L.C., AH Equity Partners Bio III, L.L.C., Marc L. Andreessen, Benjamin A. Horowitz$5.00M
333,333 shares at $15.00 on 27 Jul 2026 · filed 29 Jul 2026
Behzad Aghazadeh, Avoro Capital Advisors LLC, Avoro Ventures LLC$36.3M
2,391,238 shares at $15.16 on 24 Jul 2026 · filed 28 Jul 2026
Svetlana LucasChief Business Officer$45.0K
3,000 shares at $15.00 on 23 Jul 2026 · filed 27 Jul 2026
David ParrotChief Financial Officer$40.0K
2,666 shares at $15.00 on 23 Jul 2026 · filed 27 Jul 2026

What if Scribe Therapeutics were worth as much as…

Open the what-if tool →

Gold $29.8T

$1,576,560

Per share 59,426× higher

Bitcoin $1.69T

$89,486.00

Per share 3,373× higher

Nvidia $5.43T

$287,073.89

Per share 10,821× higher

Or at a round number

$1.00B $2.00B $5.00B $10.0B

Where these numbers come from

Share counts and financials for Scribe Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 24 Sept 2026. Read the methodology.